Tirzepatide Dosage: The Labeled and Trial-Documented Dose Schedule

The short version

Tirzepatide is given as a once-weekly injection under the skin — that is the only route used in every approved indication and every clinical trial. The standard starting dose is 2.5 mg per week for the first four weeks. After that, doses increase gradually — every four weeks — to allow the body to adjust. The goal for most people is the maximum tolerated dose, which goes up to 15 mg per week. The slow escalation is not about building drug levels (a roughly 5-day half-life means steady state is reached within a few weeks at any dose); it is about letting the gastrointestinal side effects settle between increases. The three maintenance doses studied in trials are 5, 10, and 15 mg, all given once a week.

Tirzepatide dosage: the FDA-labeled schedule

The prescribing information documents the following tirzepatide dosage regimen, applicable to both the type 2 diabetes and chronic weight management indications ^[26]:

• Starting dose: 2.5 mg subcutaneously once weekly for 4 weeks
• First maintenance increment: increase to 5 mg once weekly after 4 weeks
• Further titration (as tolerated): increase by 2.5 mg increments every 4 weeks
• Maximum labeled dose: 15 mg once weekly

The full titration ladder from 2.5 mg to 15 mg thus takes a minimum of 20 weeks (five 4-week steps). In the SURMOUNT trials, participants were escalated using this same schedule; the primary endpoint at week 72 was evaluated after participants had been on their maintenance dose for at least 50 weeks at the highest doses ^[4].

For type 2 diabetes, the maintenance dose range is 5-15 mg once weekly, depending on tolerability and glycemic response. For chronic weight management, the same dose range applies ^[26]. There is no difference in the route or schedule between indications.

Tirzepatide dose increases can be paused or returned to a lower dose if gastrointestinal adverse effects are not tolerable at a given level. The prescribing information notes that dose reduction may delay reaching the target dose but remains an option ^[26].

Tirzepatide dose: pharmacokinetics and half-life

The once-weekly dosing is possible because of tirzepatide's pharmacokinetic design. The drug's approximately five-day elimination half-life — produced by the fatty-diacid moiety that confers reversible albumin binding and protects the molecule from enzymatic clearance — means that plasma concentrations at steady state span the week between injections without falling below therapeutic levels ^[1][35].

In a phase 1 pharmacokinetic characterization, once-weekly tirzepatide in humans showed dose-proportional exposure and a half-life consistent with once-weekly dosing across a range from single ascending doses to the multiple-dose phase 1b proof-of-concept study in type 2 diabetes ^[1].

Gastric emptying is transiently delayed more on the day of injection and early in treatment than during chronic steady-state dosing, as the gastric-emptying effect of the GLP-1R-mediated component attenuates with continued exposure ^[35]. This pharmacodynamic tolerance means the gastrointestinal effects are most pronounced during the titration phase.

The subcutaneous injection can be administered in the abdomen, thigh, or upper arm. Rotating the injection site within and across these regions is the standard practice for avoiding localized skin reactions.

Tirzepatide injection: route and formulation

All clinical trials and the approved labeling specify subcutaneous injection as the only route of administration ^[26]. There is no approved oral form. No intravenous or intramuscular formulation has been studied in the phase 3 programme. The drug is formulated as a subcutaneous solution available in prefilled single-dose pens. Approved formulations are refrigerated at 36°F to 46°F (2°C to 8°C).

Five dose strengths are available in the approved labeling: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, and 15 mg/0.5 mL ^[26]. Each concentration is packaged for a single injection. The labeled formulation is not intended for reconstitution.

During documented shortage periods, compounded versions of tirzepatide appeared in the market. Regulatory authorities have raised concerns about the quality, purity, identity, and sterility of non-FDA-approved compounded sources. These concerns are documented in post-market safety reporting and are outside the scope of the approved drug record this site covers.

Doses studied in key trials

The three maintenance doses — 5, 10, and 15 mg — were the primary dose arms across the SURPASS and SURMOUNT phase 3 programmes. Key dose-response data:

SURMOUNT-1 (obesity, 72 weeks, n=2,539): mean weight changes -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. Proportions reaching at least 5%: 85%, 89%, 91% versus 35% placebo ^[4].

SURPASS-2 (type 2 diabetes, 40 weeks, n=1,879): HbA1c reductions 2.01, 2.24, 2.30 percentage points at 5, 10, 15 mg versus 1.86 pp with semaglutide 1 mg. Weight treatment differences -1.9, -3.6, -5.5 kg ^[3].

SURMOUNT-J (Japanese population, 72 weeks): estimated treatment differences versus placebo -16.1% (10 mg) and -21.1% (15 mg) ^[9].

SURPASS-CN-MONO (Chinese population, 40 weeks): HbA1c treatment differences -2.04% (5 mg), -1.93% (10 mg), -2.02% (15 mg); body-weight reductions -6.0, -6.1, -9.7 kg versus -1.0 kg with placebo ^[16].

Higher doses consistently produced greater weight reduction and HbA1c lowering at the cost of more frequent gastrointestinal adverse events during dose escalation. Discontinuation due to adverse events ranged from 4.3-7.4% across dose arms in SURMOUNT-1 ^[4].